TLX Telix Pharmaceuticals Limited

The average of price targets set by Wall Street analysts indicates a potential upside of 83.4% in Telix Pharmaceuticals Limited (TLX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Bond yields at two decade highs have reset borrowing costs across the globe, which puts pressure on heavily indebted businesses but shines a spotlight on Australian companies that can fund their own expansion. When insiders own meaningful stakes in fast growing outfits, incentives to grow carefully rather than chase cheap debt can be stronger. This article walks through three high growth, high insider ownership stocks from that group. The three stocks below are a small sample, and the full...

Telix Pharmaceuticals has delivered a very strong 185.1% share price gain over the past five years, yet the latest acquisition plans and product approvals leave a clear question about whether that journey is still backed by its cash flows. With the stock now trading around A$16.08 after a weaker recent patch, investors are increasingly focused on what the underlying cash generation can reasonably support. That 185.1% return over five years puts real weight on whether Telix’s current...

Telix Pharmaceuticals (ASX:TLX) has moved to lead a merger with ITM Isotope Technologies Munich SE, a radioisotope producer and radiopharmaceutical developer, in a transaction valued at up to A$2.35b. Telix Pharmaceuticals shares trade at A$16.08 after a sharp 1 day share price decline of 4.23% and a 7 day share price fall of 4.68% following the merger announcement. However, the year to date share price return of 41.55% and 5 year total shareholder return of 185.11% suggest longer term...

Telix Pharmaceuticals Limited (NASDAQ:TLX) agreed on September 21 to acquire ITM Isotope Technologies Munich SE. The deal is worth up to $2.35 billion. Telix will pay $1.65 billion upfront, before cash and debt. A further $700 million follows if ITM’s lead drug wins approval and hits sales targets. Telix is paying mostly in its own […]

Telix Pharmaceuticals (ASX: TLX) has agreed to acquire ITM Isotope Technologies Munich SE in a deal valued at US$2.35b. The transaction gives Telix control of a major global producer of medical radioisotopes used in cancer diagnosis and treatment. Management describes the purchase as a step toward a vertically integrated radiopharmaceutical model with broader manufacturing and commercial reach. The ITM Isotope Technologies Munich acquisition could reshape Telix's business profile, but...

Telix Pharmaceuticals announced a merger with privately held ITM on Monday, leading the stock to crash despite bullish views from analysts.

Healthcare stocks rose late Monday afternoon with the NYSE Healthcare Index increasing 0.6% and the

Healthcare stocks rose Monday afternoon, with the NYSE Healthcare Index increasing 0.5% and the Stat

Telix Pharmaceuticals (TLX) agreed to acquire Germany-based ITM Isotope Technologies Munich in a dea

The deal is expected to close by the end of the 2026 financial year, subject to Telix shareholder and regulatory approvals.

The FDA’s target date for deciding on Pixclara is September 11.

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index and the State

Healthcare stocks were higher Wednesday afternoon, with the NYSE Healthcare Index adding 0.7% and th

Telix Pharmaceuticals Ltd ADR (NASDAQ:TLX) shares rose 5. 3% in premarket trading on Wednesday as investors assessed the company’s Phase 3 BiPASS trial progress and its regulatory pathway in the U.

Rising treasury and sovereign yields driven by persistent inflation concerns are forcing investors to think harder about where future growth might justify the extra risk. This is where fast-growing stocks with high insider ownership become interesting. When management has significant skin in the game, their long-term outlook aligns more closely with yours. This article highlights three stocks from that screener that fit this theme today. The three stocks below are just a small sample of the...

With European bond yields pushing toward multi year highs on persistent inflation concerns, investors are again paying close attention to what they are actually paying for future cash flows. Higher discount rates tend to punish overhyped stories and highlight companies whose cash generation already looks attractive. This article walks through three stocks from the Undervalued Stocks Based On Cash Flows screener that appear mispriced against their SWS DCF fair values. The three stocks that...

Global demand tied to AI related investment is shaping trade and capital flows, and that is putting growth companies with clear earnings ambitions back in focus. Investors are searching for businesses that can convert this demand into real revenue, and management teams that are confident enough to back their own outlook with meaningful share ownership. This article walks through three fast growing stocks with high insider ownership that fit that brief. The three stocks below are just a...

Moby summary of Telix Pharmaceuticals Limited's Q2 2026 earnings call

Telix Pharmaceuticals Ltd (TLPPF) reports strong first-half results with EBITDA up 146%, while navigating regulatory hurdles and competitive pressures in the PSMA imaging market.

Telix Pharmaceuticals (NASDAQ:TLX) reported first-half 2026 revenue of $477 million, up 22% from the prior-year period, as demand for its precision medicine imaging products continued to grow. The company said EBITDA increased 146% year over year to $52 million, while net profit after tax rose to $3

Regeneron Pharmaceuticals reported past second-quarter 2026 results with revenue rising to US$4,290.7 million from US$3,675.6 million a year earlier, while net income slipped to US$1,296.9 million and diluted EPS from continuing operations softened to US$12.23. Alongside these mixed earnings, Regeneron recently entered a collaboration with Telix Pharmaceuticals to co-develop next-generation radiopharmaceutical oncology therapies, potentially broadening its precision-medicine footprint beyond...

Regeneron tapped the Aussie biotech to enter the radiopharma market with a multi-pronged agreement.

The average of price targets set by Wall Street analysts indicates a potential upside of 86.2% in Telix Pharmaceuticals Limited (TLX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

The facility aims to address manufacturing capacity challenges and bring production and patient administration closer together.